Cargando…
抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系
OBJECTIVE: To investigate the expression of PRDM1 and its relationship with PI3K/AKT pathway activation in extranodal NK/T cell lymphoma-nasal type. METHODS: Immunocytochemistry and Western blot were used to detect the expression of PRDM1 and p-AKT in 10 EN-NK/T-NT tissue or 3 cell lines (PRDM1-posi...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348219/ https://www.ncbi.nlm.nih.gov/pubmed/30612403 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.12.008 |
_version_ | 1783556752970612736 |
---|---|
collection | PubMed |
description | OBJECTIVE: To investigate the expression of PRDM1 and its relationship with PI3K/AKT pathway activation in extranodal NK/T cell lymphoma-nasal type. METHODS: Immunocytochemistry and Western blot were used to detect the expression of PRDM1 and p-AKT in 10 EN-NK/T-NT tissue or 3 cell lines (PRDM1-positive YT cell line, PRDM1-negative NKL and NK92 cell lines). Nanostring gene expression profiling technique was used to detect the activation of the PI3K/AKT pathway in normal nasal mucosa, PRDM1-negative and positive EN-NK/T-NT tissue. MTS was used to detect cell proliferation, and flow cytometry was used to detect cell cycle and apoptosis. RESULTS: Nanostring gene expression profiling revealed that genes associated with PI3K/AKT signaling pathway (eg, IL-7, BRCA1, ITGA8, IL2RB, FASLG, CDK2, COL27A1, CSF3R, KITLG and IL-6) were highly expressed in EN-NK/T-NT cases (P<0.05). Also, we found that p-AKT was highly expressed in YT cell line, but lower or not expressed in NK92 and NKL cells. In addition, LY294002, a PI3K/AKT pathway inhibitor, increased PRDM1 and PTEN expression in a dose dependent manner in YT cells. More importantly, YT cell were treated with 20 µmol/L LY294002 48 h, the proliferation rate was significantly decreasing (58.18% vs 100.00%, t=12.770, P=0.006), and the proportion of cells in G(1) phase was significantly increased (30.05% vs 76.93%, t=11.570, P<0.001). However, there was no significant difference in cell proliferation and cell cycle between NKL cells and control group (P>0.05). CONCLUSION: The activation of PI3K/AKT pathway is positive associated with the expression of PRDM1 in EN-NK/T-NT, and inhibition of PI3K/AKT pathway may have significant therapeutic potential for PRDM1-positive EN-NK/T-NT. |
format | Online Article Text |
id | pubmed-7348219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73482192020-07-16 抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the expression of PRDM1 and its relationship with PI3K/AKT pathway activation in extranodal NK/T cell lymphoma-nasal type. METHODS: Immunocytochemistry and Western blot were used to detect the expression of PRDM1 and p-AKT in 10 EN-NK/T-NT tissue or 3 cell lines (PRDM1-positive YT cell line, PRDM1-negative NKL and NK92 cell lines). Nanostring gene expression profiling technique was used to detect the activation of the PI3K/AKT pathway in normal nasal mucosa, PRDM1-negative and positive EN-NK/T-NT tissue. MTS was used to detect cell proliferation, and flow cytometry was used to detect cell cycle and apoptosis. RESULTS: Nanostring gene expression profiling revealed that genes associated with PI3K/AKT signaling pathway (eg, IL-7, BRCA1, ITGA8, IL2RB, FASLG, CDK2, COL27A1, CSF3R, KITLG and IL-6) were highly expressed in EN-NK/T-NT cases (P<0.05). Also, we found that p-AKT was highly expressed in YT cell line, but lower or not expressed in NK92 and NKL cells. In addition, LY294002, a PI3K/AKT pathway inhibitor, increased PRDM1 and PTEN expression in a dose dependent manner in YT cells. More importantly, YT cell were treated with 20 µmol/L LY294002 48 h, the proliferation rate was significantly decreasing (58.18% vs 100.00%, t=12.770, P=0.006), and the proportion of cells in G(1) phase was significantly increased (30.05% vs 76.93%, t=11.570, P<0.001). However, there was no significant difference in cell proliferation and cell cycle between NKL cells and control group (P>0.05). CONCLUSION: The activation of PI3K/AKT pathway is positive associated with the expression of PRDM1 in EN-NK/T-NT, and inhibition of PI3K/AKT pathway may have significant therapeutic potential for PRDM1-positive EN-NK/T-NT. Editorial office of Chinese Journal of Hematology 2018-12 /pmc/articles/PMC7348219/ /pubmed/30612403 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.12.008 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系 |
title | 抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系 |
title_full | 抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系 |
title_fullStr | 抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系 |
title_full_unstemmed | 抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系 |
title_short | 抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系 |
title_sort | 抑癌基因prdm1在结外nk/t细胞淋巴瘤-鼻型中的表达及其与pi3k/akt通路活化的关系 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348219/ https://www.ncbi.nlm.nih.gov/pubmed/30612403 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.12.008 |
work_keys_str_mv | AT yìáijīyīnprdm1zàijiéwàinktxìbāolínbāliúbíxíngzhōngdebiǎodájíqíyǔpi3kakttōnglùhuóhuàdeguānxì AT yìáijīyīnprdm1zàijiéwàinktxìbāolínbāliúbíxíngzhōngdebiǎodájíqíyǔpi3kakttōnglùhuóhuàdeguānxì AT yìáijīyīnprdm1zàijiéwàinktxìbāolínbāliúbíxíngzhōngdebiǎodájíqíyǔpi3kakttōnglùhuóhuàdeguānxì AT yìáijīyīnprdm1zàijiéwàinktxìbāolínbāliúbíxíngzhōngdebiǎodájíqíyǔpi3kakttōnglùhuóhuàdeguānxì |